-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRG-004A in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRG-004A in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRG-004A in Solid Tumor Drug Details: MRG-004A is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Activate CXCR4 For HIV in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Activate CXCR4 For HIV in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Gene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – INB-100 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.INB-100 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Drug Details:INB-100 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zalifrelimab in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zalifrelimab in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zalifrelimab in Melanoma Drug Details: AGEN-1884 (zalifrelimab) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zalifrelimab in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zalifrelimab in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zalifrelimab in Lymphoma Drug Details: AGEN-1884 (zalifrelimab) is under development for the...
-
Track & Monitor
Innovation in pharma: cell immunomodulation
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s cell immunomodulation segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on...
-
Track & Monitor
Innovation in pharma: gene splicing nucleases
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s gene splicing nucleases segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Track & Monitor
Innovation in pharma: lipase compositions
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s lipase compositions segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on...
-
Track & Monitor
Genomics in pharma: zinc-finger nucleases
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s zinc-finger nucleases segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on...
-
Track & Monitor
Cell & gene therapy in pharma: gene therapy viral vectors
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s gene therapy viral vectors segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered...